Dharti Proteins has received listing approval from BSE for 5,00,000 equity shares. This is part of a NCLT-approved resolution plan. Trading approval is still pending.

Dharti Proteins Receives BSE Listing Approval for 5 Lakh Shares

BSE has granted listing approval for 5,00,000 equity shares of Dharti Proteins Ltd.

Reader Takeaway: Listing approval is a positive regulatory step, but shares remain non-tradable until trading approval is secured.

What just happened

Dharti Proteins Limited (formerly Devika Proteins Limited) has received listing approval from BSE Limited for 5,00,000 equity shares of Rs. 10 face value. This approval is a crucial step following a resolution plan sanctioned by the National Company Law Tribunal (NCLT), Ahmedabad Bench.

Why this matters

This approval signifies progress in the implementation of the NCLT resolution plan, which is positive for stakeholders. It allows for the formal listing of these shares on the exchange, a prerequisite for eventual trading.

The backstory

The shares are being allotted as part of a resolution plan approved by the NCLT on November 18, 2025. The specific allotments include 25,000 shares for capital reduction, 4,25,000 shares to the Successful Resolution Applicant (SRA)/Promoter, and 50,000 shares to a Secured Financial Creditor.

What changes now

While the listing approval has been secured, the company is still in the process of completing corporate actions with NSDL and CDSL. The most critical next step is obtaining trading approval from the exchange. Until then, these shares cannot be traded by the public.

Risks to watch

The primary risk for investors is the delay in obtaining trading approval, which would prevent liquidity and price discovery for these newly listed shares.

Peer comparison

N/A

Context metrics (time-bound)

• NCLT Order Date: 18th November, 2025
• BSE Listing Approval Date: 16th June, 2026
• Total Shares Approved for Listing: 5,00,000
• Shares for Capital Reduction: 25,000
• Shares for SRA/Promoter: 4,25,000
• Shares for Financial Creditor: 50,000

What to track next

Investors should closely monitor further announcements from Dharti Proteins regarding the status of trading approval from the exchange.